secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2026-04-23T23:59:59+00:00
Accession:  0001193125-26-171731
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar prices $325M upsized equity offering at $92/share; net proceeds ~$350.9M
-------------------------------------------------------------------------------

- Firm shares: 3,532,609 at $92.00; underwriters exercised option for 529,891 additional shares in full.
- Net proceeds estimated at ~$350.9M after underwriting discounts and offering expenses.
- Proceeds to fund general corporate purposes, including Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata.
- Joint bookrunners include Jefferies, TD Cowen, Piper Sandler; Citigroup also bookrunner.
- Offering expected to close on April 23, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000119312526171731/0001193125-26-171731-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000119312526171731/d80358d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-171731

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer